2021.02.24
I-Mab Announces Upcoming Participation at March Conferences
I-Mab today announced its participation in conferences in March.
2021.02.10
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
I-Mab today announced that the CDE of the China NMPA has cleared the IND application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, and PK/PD of TJ210/MOR210 monotherapy in patients with advanced solid tumors.
2021.02.09
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
A registered follow-on public offering by certain pre-IPO shareholders of 3,283,950 ADSs of I-Mab has priced on February 8, 2021 at a public offering price of US$54.0 per ADS.
2021.02.05
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Selling Shareholders of I-Mab
I-Mab today announced the commencement of a proposed registered underwritten public offering by certain selling shareholders of American depositary shares, each 10 ADSs representing 23 ordinary shares of the Company.
2021.02.05
I-Mab Announces Multiple Clinical Advancements of its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
I-Mab today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody uliledlimab in advanced solid tumors.
2021.02.04
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
I-Mab today announced that the first patient has been dosed in a phase 2 clinical trial of TJ107, a novel long-acting recombinant human interleukin-7, in patients with glioblastoma multiforme (GBM) in China.
2021.01.25
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
I-Mab and MorphoSys today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States.
2020.12.24
I-Mab Announces Upcoming Participation at January Conferences
I-Mab announced its participation in upcoming conferences in January.
2020.12.14
I-Mab Added to Nasdaq Biotechnology Index
I-Mab today announced that Company’s American Depositary Shares have been selected for inclusion in the NASDAQ Biotechnology Index, based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020.
2020.12.04
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China
I-Mab today announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab in the US and China, achieving milestones as planned.